Nektar Therapeutics (ITH0) Price & Analysis

1 Followers

ITH0 Stock Chart & Stats

€71.62

Market closed

€71.62

Day’s Range― - ―

52-Week Range€18.90 - €90.68

Previous CloseN/A

VolumeN/A

Average Volume (3M)89.00

Market Cap

€2.10B

Enterprise Value€1.35K

Total Cash (Recent Filing)€568.60M

Total Debt (Recent Filing)€143.43M

Price to Earnings (P/E)―

Beta2.56

Next Earnings

Aug 06, 2026

EPS Estimate

-1.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-8.42

Shares Outstanding33,786,034

10 Day Avg. Volume77

30 Day Avg. Volume89

Financial Highlights & Ratios

PEG Ratio-0.36

Price to Book (P/B)7.94

Price to Sales (P/S)12.91

P/FCF Ratio-3.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€135.38

Price Target Upside89.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-7.84

Revenue Forecast (FY)€36.27M

Bulls Say, Bears Say

Bulls Say

Phase III InitiationMoving REZPEG into global registrational ZENITH AD trials represents a durable clinical de-risking step: it transitions the program from proof-of-concept to confirmatory studies, solidifying regulatory paths and enabling a clear commercialization timeline that will matter across the 2–6 month horizon and beyond.

Robust Phase IIb EfficacyDurable, deepening Phase IIb results (EASI-100 increases, sustained EASI-75/90 and itch improvement) strengthen the product’s clinical profile and regulatory argument. Such sustained efficacy supports label differentiation and physician adoption potential, affecting mid-term commercial viability and payer discussions.

Fortified Balance Sheet And RunwayA >$1B pro forma cash position and explicit runway into Q3 2028 materially reduces near-term financing pressure and allows the company to fund multiple Phase III programs and manufacturing scale-up without immediate dilution, preserving strategic optionality over the medium term.

Bears Say

Persistent Negative Cash FlowSustained negative operating and free cash flow (~-$204M TTM) means the company will remain reliant on financing or large royalties to fund development. This ongoing burn creates structural funding risk and could force dilutive raises or program prioritization over the next several quarters.

Very Large Operating And Net LossesDeep negative margins driven by high R&D and operating costs indicate the business is far from break-even. Persistent large losses constrain returns and increase dependence on capital markets or partners, which is a durable constraint on shareholder value creation until commercialization occurs.

Execution & Regulatory Risks For Global Phase IIIsLarge, global Phase III programs create execution risk: site activation, CRO management, regional regulatory alignment and enrollment timing can materially delay readouts or increase costs. These operational challenges are structural for multinational registrational trials and affect timelines and capital needs over months.

Nektar Therapeutics News

Nektar initiated with a Buy at Canaccord on rezpegaldesleukin potential

As previously reported, Canaccord analyst Edward Nash initiated coverage of Nektar (NKTR) with a Buy rating and $153...

4d ago

NKTR

Nektar initiated with a Buy at Canaccord

Canaccord analyst Edward Nash initiated coverage of Nektar (NKTR) with a Buy rating and $153 price target Published...

4d ago

NKTR

Nektar begins Phase 3 program of rezpegaldesleukin in atopic dermatitis

Nektar (NKTR) announced the initiation of the first two global registrational trials in the Phase 3 ZENITH AD...

5d ago

NKTR

Keel, Nektar, Infleqtion, Coinbase, Autodesk Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($KEEL) ), ( ($NKTR) ), ( ($INFQ) ), ( ($COIN)...

23h ago

ADSK

COIN

Nektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock

Nektar Therapeutics ($NKTR) announced an update on their ongoing clinical study. Nektar Therapeutics is running a Phase 3...

9d ago

NKTR

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

Canaccord analyst Edward Nash says AbbVie’s (ABBV) reported $10.9B takeover of Apogee Therapeutics (APGE) equates to roughly $144...

1M ago

ABBV

APGE

Nektar Stockholders Approve Governance and Incentive Plan Changes

The latest announcement is out from Nektar Therapeutics ( ($NKTR) ). At Nektar Therapeutics’ Annual Meeting of Stockholders...

2M ago

NKTR

Nektar management to meet with Piper Sandler

Investor Luncheon to be held on June 1 hosted by Piper Sandler. Published first on TheFly – the...

2M ago

NKTR

5 Healthcare Stocks Set to Join the Russell 3000

FTSE Russell has released its preliminary changes for the Russell 3000 Index ahead of the official rebalancing on...

2M ago

QSI

AGEN

3 Best Healthcare Stocks to Buy in May 2026, According to Analysts

Healthcare stocks are back in focus this month as investors look for strong pipelines and steady growth in...

2M ago

CRNX

LEGN

Nektar price target lowered to $80 from $95 at Wedbush

Wedbush analyst Martin Fan lowered the firm’s price target on Nektar (NKTR) to $80 from $95 and keeps...

3M ago

NKTR

Nektar Therapeutics Charts Aggressive Path With REZPEG

Nektar Therapeutics (($NKTR)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

NKTR

Nektar Therapeutics Establishes New Equity Distribution Agreement

Nektar Therapeutics ( ($NKTR) ) has issued an update. On May 8, 2026, Nektar Therapeutics entered into an...

3M ago

NKTR

Julian Harrison Reiterates Buy on Nektar, Citing Robust REZPEG Program and Strong Balance Sheet; Maintains $178 Price Target

BTIG analyst Julian Harrison has maintained their bullish stance on NKTR stock, giving a Buy rating today. Julian...

3M ago

NKTR

ITH0 FAQ

What was Nektar Therapeutics’s price range in the past 12 months?

Nektar Therapeutics lowest stock price was €18.90 and its highest was €90.68 in the past 12 months.

What is Nektar Therapeutics’s market cap?

Nektar Therapeutics’s market cap is €2.10B.

When is Nektar Therapeutics’s upcoming earnings report date?

Nektar Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.

How were Nektar Therapeutics’s earnings last quarter?

Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -€1.599 earnings per share for the quarter, missing the consensus estimate of -€1.389 by -€0.209.

Is Nektar Therapeutics overvalued?

According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nektar Therapeutics pay dividends?

Nektar Therapeutics does not currently pay dividends.

What is Nektar Therapeutics’s EPS estimate?

Nektar Therapeutics’s EPS estimate is -1.73.

How many shares outstanding does Nektar Therapeutics have?

Nektar Therapeutics has 33,786,034 shares outstanding.

What happened to Nektar Therapeutics’s price movement after its last earnings report?

Nektar Therapeutics reported an EPS of -€1.599 in its last earnings report, missing expectations of -€1.389. Following the earnings report the stock price went down -6.179%.

Which hedge fund is a major shareholder of Nektar Therapeutics?

Currently, no hedge funds are holding shares in DE:ITH0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nektar Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

197.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Nektar Therapeutics (ITH0) Earnings & Revenues

Historic Earnings Reports

ITH0 Stock 12 Month Forecast

Average Price Target

€135.38

▲(89.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","55":"€55","93":"€93","131":"€131","169":"€169"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":168.6339168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€168.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135.38392576428572,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€135.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.264132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€70.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,55,93,131,169],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.18,68.52260898461539,76.86521796923077,85.20782695384615,93.55043593846153,101.89304492307693,110.23565390769231,118.57826289230769,126.92087187692309,135.26348086153845,143.60608984615385,151.94869883076925,160.2913078153846,{"y":168.6339168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.18,65.96491736648352,71.74983473296703,77.53475209945054,83.31966946593407,89.10458683241758,94.88950419890111,100.67442156538462,106.45933893186813,112.24425629835164,118.02917366483516,123.81409103131868,129.5990083978022,{"y":135.38392576428572,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.18,60.955702461538465,61.73140492307692,62.50710738461539,63.282809846153846,64.05851230769231,64.83421476923077,65.60991723076923,66.3856196923077,67.16132215384616,67.93702461538462,68.71272707692307,69.48842953846155,{"y":70.264132,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.08,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >